Unigene Laboratories (UGNE) Inactive 10-Q2011 Q1 Quarterly report

Filed: 10 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: advance, advanced, advancement, advancing, Agency, amortizable, Annexin, anorexigenic, appetite, arm, authoritative, baseline, charge, commensurate, companion, concept, consent, conservancy, conserve, consulting, cumulative, customer, customizing, defense, Delaware, density, Directed, disagreement, discontinued, distinct, distinctive, divesting, document, dose, effort, EMA, endpoint, enhanced, enhancement, escrow, Estate, European, evidence, expended, exploiting, exploring, extension, extensive, fifty, forbearance, formalized, foundation, founded, founding, gave, goal, growing, hearing, hope, incremental, IND, indefinitely, industry, inflammatory, intangible, Investigational, label, leadership, low, MAA, mandatorily, maximizing, maximum, mineral, monthly, morbidly, multicenter, objective, open, opportunity, ORACAL, organizational, osteoporotic, Peptelligence, PeptelligenceTM, pharmacologically, placebo, portfolio, postponed, Preferred, proof, Protocol, prudent, put, Rabbi, rata, receipt, recombinantly, reorganization, repeat, reproducible, retiring, return, revised, satiety, satisfaction, scalable, segment, service, settle, settled, settlement, shareholder, single, sister, situational, slight, socioeconomic, solid, SPA, stability, stake, statistically, steadily, stipulated, subsidize, TM, Trust, undelivered, upfront, veterinary, waived, women, writing

Removed: abbreviated, ac, acquire, adversely, allocated, allocation, book, cardiovascular, chemical, close, combined, commercialized, compete, completi, consistent, constant, consummate, cts, decreasing, defining, deliverable, determining, developing, domestic, duly, ective, eff, eliminate, enable, enjoined, excluding, exhibit, expand, forecast, fourth, fundamental, good, Hatch, hieved, higher, huma, Implementation, incur, infringe, integrated, intere, largely, launch, London, manner, month, negative, netted, notice, operate, perform, periodically, permitted, Practice, produ, professional, profitable, rapid, redemption, salary, separately, st, standard, stated, Steinhauer, sued, tha, thereof, thereunto, trademarked, undersigned, update, Waxman, William, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

UGNE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Unigene Laboratories, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William Steinhauer, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ William Steinhauer

---------------------------------------------

William Steinhauer

Vice President of Finance

Principal Financial Officer

May 10, 2011

A signed original of this written statement required by Section 906 has been provided to Unigene Laboratories, Inc. and will be retained by Unigene Laboratories, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.